Office: 09056 Salk Hall
Katherine Robinson, PharmD, BCPS Clinical Pharmacogenomics Fellow,
Katherine is from Hernando, Mississippi, and received her PharmD at the University of Tennessee Health Science Center College of Pharmacy in Memphis, TN. She completed PGY1 training at the University of Kentucky and PGY2 training in Clinical Pharmacogenomics at St. Jude Children's Research Hospital. Her research interests include studying genetic predictors of long-term outcomes of medications and implementation science to improve uptake of pharmacogenomic recommendations in clinical practice. Her clinical interests include implementation of pharmacogenomics in high-risk populations and pediatric hematology/oncology.
Clinical utility of pharmacogenomics to improve patient outcomes, implementation of pharmacogenomics, hematology/oncology, pediatrics
Robinson KM, Yang W, Karol SE, Kornegay N, Jay D, Cheng C, Choi JK, Campana D, Pui C, Wood B, Borowitz MJ, Gastier-Foster J, Larsen EC, Winick N, Carroll WL, Loh ML, Raetz EA, Hunger SP, Devidas M, Mardis ER, Fulton RS, Relling MV, Jeha S. No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. Pediatr Blood and Cancer; 2019; 66(6): e27681.
Robinson KM, Yang W, Haidar CE, Hankins JS, Jay DW, Kornegay N, Rubnitz JE, Broeckel U, Cheng C, Pui C, Jeha S, Relling MV. Concordance between glucose-6-phosphate-dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies. Pharmacogenomics Journal; 2018: doi:10.1038/s41397-018-0043-3.
ISCC-PEG Scholar 2020-2022